Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice-Reference-Cited by-同舟云学术

Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice

Published:2017-03-08 Issue:6 Volume:158 Page:1701-1714
ISSN:0013-7227
Container-title:Endocrinology
language:en
Short-container-title:

Author:

Cox Aaron R.¹,Lam Carol J.¹,Rankin Matthew M.²,Rios Jacqueline S.¹,Chavez Julia¹,Bonnyman Claire W.¹,King Kourtney B.²,Wells Roger A.³⁴,Anthony Deepti¹,Tu Justin X.²,Kim Jenny J.²,Li Changhong²,Kushner Jake A.¹

Affiliation:

1. McNair Medical Institute, Pediatric Diabetes and Endocrinology, Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas 77030

2. Division of Endocrinology and Diabetes, Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104

3. Department of Cellular, Molecular, and Biomedical Sciences, University of New Hampshire, Durham, New Hampshire 03824

4. Consulting Tox/Path Services, Kittery, Maine 03904

Publisher

The Endocrine Society

Subject

Endocrinology

Link

http://academic.oup.com/endo/article-pdf/158/6/1701/17643661/en.2017-00027.pdf

Reference52 articles.

1. ATP-sensitive potassium channelopathies: focus on insulin secretion;Ashcroft;J Clin Invest,2005

2. Pharmacology, physiology, and mechanisms of incretin hormone action;Campbell;Cell Metab,2013

3. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006